Published in Top Antivir Med on November 01, 2011
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology (2014) 3.15
A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol (2013) 1.15
HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS One (2013) 1.11
HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. J Neurovirol (2014) 1.10
Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis (2013) 0.94
Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens. J Neurochem (2013) 0.91
HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp Neurol (2013) 0.91
Early viral suppression improves neurocognitive outcomes in HIV-infected children. AIDS (2015) 0.89
HIV-associated neurocognitive disorders. J Mol Psychiatry (2014) 0.89
Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol Neurodegener (2014) 0.87
The HIV-1 transgenic rat model of neuroHIV. Brain Behav Immun (2015) 0.87
Endothelin-1 and its role in the pathogenesis of infectious diseases. Life Sci (2014) 0.86
Protease resistant protein cellular isoform (PrP(c)) as a biomarker: clues into the pathogenesis of HAND. J Neuroimmune Pharmacol (2013) 0.85
HIV increases the release of dickkopf-1 protein from human astrocytes by a Cx43 hemichannel-dependent mechanism. J Neurochem (2013) 0.85
Neuronal toxicity in HIV CNS disease. Future Virol (2012) 0.85
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. PLoS One (2013) 0.84
Auditory impairments in HIV-infected individuals in Tanzania. Ear Hear (2014) 0.84
CCR5 blockade for neuroinflammatory diseases - beyond control of HIV. Nat Rev Neurol (2016) 0.83
Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. J Neurovirol (2015) 0.82
Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence. AIDS Care (2014) 0.82
HIV eradication symposium: will the brain be left behind? J Neurovirol (2015) 0.82
Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study. AIDS (2015) 0.81
Efavirenz induces neuronal autophagy and mitochondrial alterations. J Pharmacol Exp Ther (2014) 0.81
HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. Med Microbiol Immunol (2016) 0.81
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol (2015) 0.81
Immune markers predictive of neuropsychiatric symptoms in HIV-infected youth. Clin Vaccine Immunol (2014) 0.80
The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. CNS Drugs (2016) 0.80
Complement and HIV-I infection/HIV-associated neurocognitive disorders. J Neurovirol (2014) 0.80
Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. J Neurovirol (2015) 0.79
Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection. HIV Med (2015) 0.79
Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics. Neurotox Res (2016) 0.79
Induction of P-glycoprotein by antiretroviral drugs in human brain microvessel endothelial cells. Antimicrob Agents Chemother (2013) 0.78
Autophagy in Mycobacterium tuberculosis and HIV infections. Front Cell Infect Microbiol (2015) 0.77
HIV-associated neurocognitive disorders: perspective on management strategies. Drugs (2013) 0.77
HIV-tat alters Connexin43 expression and trafficking in human astrocytes: role in NeuroAIDS. J Neuroinflammation (2016) 0.76
Modeling HIV-1 Induced Neuroinflammation in Mice: Role of Platelets in Mediating Blood-Brain Barrier Dysfunction. PLoS One (2016) 0.76
Dual-mixed HIV-1 coreceptor tropism and HIV-associated neurocognitive deficits. J Neurovirol (2013) 0.75
A Critical Review of the Evidence Concerning the HIV Latency Reversing Effect of Disulfiram, the Possible Explanations for Its Inability to Reduce the Size of the Latent Reservoir In Vivo, and the Caveats Associated with Its Use in Practice. AIDS Res Treat (2017) 0.75
The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study. Clin Infect Dis (2016) 0.75
HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology (2016) 0.75
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. HIV AIDS (Auckl) (2015) 0.75
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (2010) 4.41
Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology (2005) 2.45
HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A (2002) 2.31
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS (2005) 2.25
Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS (2009) 2.16
Neurologic complications of HIV disease and their treatment. Top HIV Med (2010) 2.14
Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology (2009) 2.00
Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr (2009) 1.81
HIV-1 infection and cognitive impairment in the cART era: a review. AIDS (2011) 1.72
Biomarkers of HIV-1 CNS infection and injury. Neurology (2007) 1.69
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis (2007) 1.63
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS (2010) 1.45
Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis (2005) 1.35
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother (2010) 1.19
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother (2002) 1.04
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS (2009) 0.96
The importance of cognitive self-report in early HIV-1 infection: validation of a cognitive functional status subscale. AIDS (2002) 0.88
HIV-associated deficits in action (verb) generation may reflect astrocytosis. J Clin Exp Neuropsychol (2009) 0.83
Motor based assessment of neurocognitive functioning in resource-limited international settings. J Clin Exp Neuropsychol (2007) 0.83
Blood-CSF barrier and compartmentalization of CNS cellular immune response in HIV infection. J Neuroimmunol (2016) 0.76